Expression and clinical implications of HAb18G/CD147 in hepatocellular carcinoma

Hepatology Research

Volumn 45, Issue 1, 2015, Pages 97-106

  Zhu, Shaojun ^a   Li, Yanhong ^a   Zhang, Yang ^b   Wang, Xuxia ^a   Gong, Li ^a   Han, Xiujuan ^a   Yao, Li ^a   Lan, Miao ^a   Zhang, Wei ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HAb18G CD147; Hepatocellular carcinoma; Immunohistochemistry; Survival

Indexed keywords

CD147 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER TISSUE; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER CELL LINE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; TISSUE DISTRIBUTION; TUMOR DIFFERENTIATION; VIRUS CARCINOGENESIS; WESTERN BLOTTING;

EID: 84921057207     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12320     Document Type: Article

References (47)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
2. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-2324.
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
4. Korangy F, Ormandy LA, Bleck JS etal. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 4332-4341.
5. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005; 65: 2457-2464.
6. Biswas C, Zhang Y, DeCastro R etal. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55: 434-439.
7. Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell 2004; 15: 4043-4050.
8. Yan L, Zucker S, Toole BP. Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 2005; 93: 199-204.
9. Kirk P, Wilson MC, Heddle C etal. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 2000; 19: 3896-3904.
10. Xu D, Hemler ME. Metabolic activation-related CD147-CD98 complex. Mol Cell Proteomics 2005; 4: 1061-1071.
11. Berditchevski F, Chang S, Bodorova J etal. Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. J Biol Chem 1997; 272: 29174-29180.
12. Curtin KD, Meinertzhagen IA, Wyman RJ. Basigin (EMMPRIN/CD147) interacts with integrin to affect cellular architecture. J Cell Sci 2005; 118: 2649-2660.
13. Gordon JM, Bauer EA, Eisen AZ. Collagenase in human cornea: immunologic localization. Arch Ophthalmol 1980; 98: 341-345.
14. Wagoner MD, Kenyon KR. Distribution of collagenase and cell types in sterile ulceration of human corneal grafts. Acta Ophthalmol 1989; 192: 65-71.
15. Major TC, Liang L, Lu X, Rosebury W, Bocan TM. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 2002; 22: 1200-1207.
16. Li Z, Ren Y, Wu QC etal. Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrixmetalloproteinase 9 and interleukin-8 in nasopharyngeal carcinoma cell lines. J Chin Med 2004; 117: 107-114.
17. Zucker S, Hymowitz M, Rollo EE etal. Tumorigenic potential of extracellular matrixmetalloproteinase inducer. Am J Pathol 2001; 158: 1921-1928.
18. Ramos-Simone N, Hahn-Dantona E, Sipley J etal. Activation of matrix metalloprotease-9 (MMP-9) via a converting Plasmin/Stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999; 274: 13066-13076.
19. Davidson B, Goldberg I, Berner A etal. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003; 20: 161-169.
20. Guo H, Li R, Zucker S etal. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res 2000; 60: 888-891.
21. Bourguignon L, Gunja-Smith Z, Iida N etal. CD44v (3, 8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 1998; 176: 206-215.
22. Li Z, Ren Y, Wu QC etal. Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrix metalloproteinase 9 and interleukin-8 in nasopharyngeal carcinoma cell lines. Chin Med J 2004; 117: 107-114.
23. Tang J, Zhou HW, Jiang JL etal. βig-h3 is involved in the CD147/CD147-mediated metastasis process in human hepatoma cells. Exp Biol Med 2007; 232: 344-352.
24. Cheng MF, Tzao C, Tsai WC etal. Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus 2006; 19: 482-486.
25. Tang J, Wu YM, Zhao P, Yang XM, Jiang JL, Chen ZN. Overexpression of CD147/CD147 promotes invasion and metastasis via a3b1 integrin mediated FAK-paxillin and FAK-PI3K-Ca2+ pathways. Cell Mol Life Sci 2008; 65: 2933-2942.
26. Kuniholm MH, Lesi OA, Mendy M etal. Aflatoxin exposure and viral hepatitis in the etiology of liver cirrhosis in the Gambia, West Africa. Environ Health Perspect 2008; 116: 1553-1557.
27. Iwasa S, Jin X, Okada K etal. Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett 2003; 199: 91-98.
28. Ariga N, Sato E, Ohuchi N, Nagura H, Ohtani H. Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer 2001; 95: 67-72.
29. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32 (Suppl 1): 88-102.
30. Liu Y, Lou G, Chen Z. Research advances on treatment of hepatitis C infection based on RNA interference and microRNA modulation. Zhejiang Da Xue Xue Bao Yi Xue Ban 2011; 40: 609-616.
31. Tolmane I, Rozentale B, Keiss J, Arsa F, Brigis G, Zvaigzne A. The prevalence of viral hepatitis C in Latvia: a population-based study. Medicina (Kaunas) 2011; 47: 532-535.
32. Polette M, Gilles C, Marchand V etal. Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers. J Histochem Cytochem 1997; 45: 703-709.
33. Yu W, Liu J, Xiong X, Ai Y, Wang H. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract 2009; 205: 709-715.
34. Riethdorf S, Reimers N, Assmann V etal. High incidence of EMMPRIN expression in human tumors. Int J Cancer 2006; 119: 1800-1810.
35. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 2006; 56: 359-367.
36. Hasaneen NA, Zucker S, Cao J, Chiarelli C, Panettieri RA, Foda HD. Cyclic mechanical strain-induced proliferation and migration of human airway smooth muscle cells: role of EMMPRIN and MMPs. FASEB J 2005; 19: 1507-1509.
37. Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Insights into the pathobiology of hepatitis C virus-associated cirrhosis: analysis of intrahepatic differential gene expression. Am J Pathol 2002; 160: 641-654.
38. Waldow T, Witt W, Buzin A, Ulmer A, Matschke K. Prevention of ischemia/reperfusion-induced acc umulation of matrix metallopro-teinases in rat lung by preconditioning with nitric oxide. J Surg Res 2009; 152: 198-208.
39. Yurchenko V, Constant S, Bukrinsky M. Dealing with the family: CD147 interactions with cyclophilins. Immunology 2006; 117: 301-309.
40. Chen X, Su J, Chang J etal. Inhibition of CD147 gene expression via RNA interference reduces tumor cell proliferation, activation, adhesion, and migration activity in the human Jurkat T-lymphoma cell line. Cancer Invest 2008; 26: 689-697.
41. Liu CJ, Liou JM, Chen DS, Chen PJ. Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. J Formos Med Assoc 2005; 104 (11): 783-791.
42. Squadrito G, Orlando ME, Pollicino T etal. Virological profiles in patients with chronic hepatitis C and overt or occult HBV infection. Am J Gastroenterol 2002; 97 (6): 1518-1523.
43. Lee LP, Dai CY, Chuang WL etal. Comparison of liver histopathology between chronic hepatitis C patients and chronic hepatitis B and C-coinfected patients. J Gastroenterol Hepatol 2007; 22 (4): 515-517.
44. Kirk GD, Lesi OA, Mendy M etal. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004; 39 (1): 211-219.
45. Flores Y, Lang C, Salmero'n J, Bastani R. Risk factors for liver disease and associated knowledge and practices among Mexican adults in the US and Mexico. J Community Health 2012; 37: 403-411.
46. Herzer K, Sprinzl M, Galle P. Hepatitis viruses: live and let die. Liver Int 2007; 27: 293-301.
47. Gurtsevitch V. Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc) 2008; 73: 504-513.